<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B4B67041-2B73-4786-BDA5-20CA8E9BF709"><gtr:id>B4B67041-2B73-4786-BDA5-20CA8E9BF709</gtr:id><gtr:name>University of Kansas</gtr:name><gtr:address><gtr:line1>University of Kansas</gtr:line1><gtr:line4>Lawrence</gtr:line4><gtr:line5>Kansas</gtr:line5><gtr:postCode>KS 66045</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Inst of Molecular &amp; Cellular Biology</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B4B67041-2B73-4786-BDA5-20CA8E9BF709"><gtr:id>B4B67041-2B73-4786-BDA5-20CA8E9BF709</gtr:id><gtr:name>University of Kansas</gtr:name><gtr:address><gtr:line1>University of Kansas</gtr:line1><gtr:line4>Lawrence</gtr:line4><gtr:line5>Kansas</gtr:line5><gtr:postCode>KS 66045</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5C8A3C85-A7DE-4BA6-AF73-BC9BB51E06D3"><gtr:id>5C8A3C85-A7DE-4BA6-AF73-BC9BB51E06D3</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Griffin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700124"><gtr:id>92B43EE0-E0FB-4543-BE0F-70A17B831761</gtr:id><gtr:title>Interplay between hepatitis C virus structural proteins and the p7 ion channel during particle assembly</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700124</gtr:grantReference><gtr:abstractText>Over 170 million people currently live with hepatitis C virus (HCV); although most are not aware that they are positive as the initial illness is extremely mild. Decades later, however, symptoms appear and many patients require liver transplants due to the development of severe liver damage, known as cirrhosis, or even liver cancer. In developed countries, drug combinations can be used to treat these patients, although these only work in about 50% of cases and have severe side-effects. As a result of failed treatment, 10 000 individuals died from HCV infection last year in the USA alone.
Until very recently, researchers have been unable to grow HCV in the laboratory, which has severely limited progress on developing new drugs to combat infection. In 2005, however, a new strain of the virus that could be grown in culture was discovered. This meant that for the first time, the way in which individual virus particles are made within the cell could be studied, providing a new area for drug discovery.
Virus particles are made of a protein shell, or core, that surrounds the genome and many, including HCV, have a second membranous shell known as the envelope which contains proteins that allow the virus to enter new cells. The construction of a new particle within an infected cell is a complex process, so the virus hijacks host cell machinery to achieve it. One strategy the virus employs is to make proteins that alter the environment within the cell, making it suitable for the assembly of new virus particles. For HCV, this protein is known as p7. I discovered that p7 is able to form seven-membered pores in membranes, which alter how acidic various parts of the cell become. I also showed that a drug called amantadine can prevent p7 from doing this.
My study will test whether drugs like amantadine can be used to stop HCV spreading in culture, which is the first step towards developing new clinical treatments. I will then investigate how these pores affect the other particle components during assembly and where in the cell this takes place. I will then use a fluorescent HCV to track, under the microscope, the route which particles take when leaving a live cell. Lastly, I will determine which parts of the cellular machinery HCV manipulates in order to create new particles, which could highlight targets for future drug development.</gtr:abstractText><gtr:technicalSummary>Hepatitis C virus (HCV) chronically infects over 3 % of the worlds!
 population and is the leading indicator for liver transplant surgery. Unfortunately, the majority of carriers are unaware of their positive status as acute infection is usually asymptomatic, yet the majority ( 80 %) develop persistent infection. It is only after many years when symptoms present as a consequence of severe liver damage that clinical intervention takes place. Current therapy comprising interferon ?? combined with ribavirin, however, is expensive, poorly tolerated and ineffective in up to 50 % of cases. Thus, the search for new anti-HCV drugs is a priority, although these have been slow in development due to an inability to grow the virus in culture. Interestingly, clinical trials where amantadine was included alongside current therapies have shown encouraging results.
Recently, a cell culture system for HCV was described based on a unique virus isolate, JFH-1. This represents the most important break-through in HCV research to date and provides the first opportunity to study the processes involved in the formation of HCV virions. A key factor implicated in HCV assembly is the p7 protein, which I demonstrated to function as an amantadine-sensitive ion channel; thus providing a potential mechanism for the clinical action of the drug.
This proposal will build on my work characterising p7 and use JFH-1 to validate candidate p7 inhibitors as a means of blocking HCV replication in culture. Virus inhibition assays will be complemented by a novel in vitro assay for p7 channel function using recombinant protein. I will then use a unique anti-JFH-1 p7 antibody to examine the effects caused by a loss of p7 function on other HCV proteins, focusing on the stability of the viral core and envelope proteins. This will lead to an extensive examination of where HCV assembles within the cell and the route by which virions are secreted; combining live cell imaging of fluorescently labelled virus with cell fractionation, immunofluorescence and EM studies. The cellular processes hijacked by HCV to exit the cell will then be examined by characterising potential interactions with host vesiclular sorting machinery, providing further targets for therapy. Lastly, an additional role for p7 during virus entry will be investigated by determining whether p7 comprises part of the HCV virion. These studies will both provide an insight into a hitherto uncharacterised aspect of the HCV life-cycle and validate p7 as a target for future therapies.</gtr:technicalSummary><gtr:fund><gtr:end>2011-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>275105</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>University of Texas Medical Branch (UTMB)</gtr:department><gtr:description>p7 function in cells with Prof Steven Weinman</gtr:description><gtr:id>98E9F1AB-7F0E-4A30-A8FB-F5137D34D61B</gtr:id><gtr:impact>International HCV meeting, poster presentation 2008, 2009. Oral presentation 2010. Publication 20824094.</gtr:impact><gtr:partnerContribution>Together investigated HCV p7 ion channel function in mammalian cells and correlated effect of antivirals with block of ion channel functionTogether investigated HCV p7 ion channel function in mammalian cells and correlated effect of antivirals with block of ion channel function</gtr:partnerContribution><gtr:piContribution>Together investigated HCv p7 ion channel function in mammalian cells and correlated effect of antivirals with block of ion channel function</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Kansas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>p7 function in cells with Prof Steven Weinman</gtr:description><gtr:id>F69067F5-C721-45FB-BF17-8AD8406FFFFE</gtr:id><gtr:impact>International HCV meeting, poster presentation 2008, 2009. Oral presentation 2010. Publication 20824094.</gtr:impact><gtr:partnerContribution>Together investigated HCV p7 ion channel function in mammalian cells and correlated effect of antivirals with block of ion channel functionTogether investigated HCV p7 ion channel function in mammalian cells and correlated effect of antivirals with block of ion channel function</gtr:partnerContribution><gtr:piContribution>Together investigated HCv p7 ion channel function in mammalian cells and correlated effect of antivirals with block of ion channel function</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Institute for Biological Standards and Control (NIBSC)</gtr:department><gtr:description>Chimeric GBVB/HCV with Dr Nicola Rose (NIBSC)</gtr:description><gtr:id>4C50617C-3674-42DA-8BB8-AD7ADF5A9A77</gtr:id><gtr:impact>Publication - 18845353</gtr:impact><gtr:partnerContribution>NIBSC performed animal experiments on Tamarins infected with novel chimeric GBV-B expressing HCV p7 protein.</gtr:partnerContribution><gtr:piContribution>Leeds - Chimeras designed and generated and biochemical characterisation performed. GSK - animal work.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Novel GSk compounds</gtr:description><gtr:id>A3713DF9-3278-4B1A-8C94-A066447D2424</gtr:id><gtr:impact>Publication - 18828153</gtr:impact><gtr:partnerContribution>Provision of reagents</gtr:partnerContribution><gtr:piContribution>provision of reagents</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Biological Sciences Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>ESCRT pathway with Dr Colin Crump</gtr:description><gtr:id>CB40207E-D82B-4E9C-83F4-BB842496CE21</gtr:id><gtr:impact>Publication - 19828764 Oral presentations at Society for General Microbiology AGM 2008, UK HCV meeting 2009.</gtr:impact><gtr:partnerContribution>Provision of reagents and advice on research planning.</gtr:partnerContribution><gtr:piContribution>Together identified the dependence of HCv on the cell ESCRT pathway during particle production.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine Southampton</gtr:department><gtr:description>HCV assembly with Dr Chris McCormick</gtr:description><gtr:id>42F23126-D75B-4BED-9B97-FB53E2E7B88E</gtr:id><gtr:impact>Publication - 19223490</gtr:impact><gtr:partnerContribution>Collaborative project on HCV assembly</gtr:partnerContribution><gtr:piContribution>Establishment of surrogate HCv assembly system</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>D62B1745-0BF9-4126-B7C5-CA59D7270C40</gtr:id><gtr:impact>Press release organised by University firm, &amp;quot;Campus PR&amp;quot;

Lead feature on University of Leeds Website, also posted in several HCV patient websites</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release 2 - Hepatology paper 2011</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ED6B5945-0847-4000-B8F4-ED5F23CBCE4F</gtr:id><gtr:impact>Press release taken up by local press, University, MRC and numerous patient websites as well as the Japanese Medical Tribune.

Numerous research groups have approached us to test their candidate p7 inhibitors.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.leeds.ac.uk/news/article/2191/</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>royal society project grant</gtr:description><gtr:end>2009-02-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>145CB1B6-C051-49FF-9FE8-F54D36E65505</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Yorkshire Cancer Research Pump-priming grant</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>Yorkshire Cancer Research</gtr:fundingOrg><gtr:id>6CFBC8FF-CF2C-4F52-8596-C189D5674E11</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4935BCC8-027C-4851-931C-5EF7C2404893"><gtr:id>4935BCC8-027C-4851-931C-5EF7C2404893</gtr:id><gtr:title>The subcellular localization of the hepatitis C virus non-structural protein NS2 is regulated by an ion channel-independent function of the p7 protein.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b4fd412bd7f43472d0892d02c8f29361"><gtr:id>b4fd412bd7f43472d0892d02c8f29361</gtr:id><gtr:otherNames>Tedbury P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/89770A48-05DA-4EC7-83CD-FF7BBADBD6F0"><gtr:id>89770A48-05DA-4EC7-83CD-FF7BBADBD6F0</gtr:id><gtr:title>Hepatitis C virus-induced autophagy is independent of the unfolded protein response.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c3c25cea7bc022d57defdcd8bfddb98"><gtr:id>4c3c25cea7bc022d57defdcd8bfddb98</gtr:id><gtr:otherNames>Mohl BP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/412ADF60-B791-4763-A7CD-CB181083796B"><gtr:id>412ADF60-B791-4763-A7CD-CB181083796B</gtr:id><gtr:title>Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24d87c50db64b39131deacbf06e2fe80"><gtr:id>24d87c50db64b39131deacbf06e2fe80</gtr:id><gtr:otherNames>Mankouri J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C28A94F1-1C9F-41DF-A5D8-BEE35CE95619"><gtr:id>C28A94F1-1C9F-41DF-A5D8-BEE35CE95619</gtr:id><gtr:title>Mutations in hepatitis C virus p7 reduce both the egress and infectivity of assembled particles via impaired proton channel function.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/108d7f9bb5eedbb4e82ebe3c4c0525b7"><gtr:id>108d7f9bb5eedbb4e82ebe3c4c0525b7</gtr:id><gtr:otherNames>Bentham MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D126AA0F-56B0-4A07-91CF-2B0570B1B13D"><gtr:id>D126AA0F-56B0-4A07-91CF-2B0570B1B13D</gtr:id><gtr:title>Genotype-specific differences in structural features of hepatitis C virus (HCV) p7 membrane protein.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/065a6b00ecc1c2c772221e15a38fbb0f"><gtr:id>065a6b00ecc1c2c772221e15a38fbb0f</gtr:id><gtr:otherNames>Kalita MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AA9604E2-4FAA-45E0-B6BB-415C8DD3F9CC"><gtr:id>AA9604E2-4FAA-45E0-B6BB-415C8DD3F9CC</gtr:id><gtr:title>Identification of a novel phosphorylation site in hepatitis C virus NS5A.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fcbb98f3699e3e5627e356b91424e20c"><gtr:id>fcbb98f3699e3e5627e356b91424e20c</gtr:id><gtr:otherNames>Nordle Gilliver A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1CDDA025-33E2-413D-B2F3-AC4CCF0047A9"><gtr:id>1CDDA025-33E2-413D-B2F3-AC4CCF0047A9</gtr:id><gtr:title>Genetic and functional heterogeneity of the hepatitis C virus p7 ion channel during natural chronic infection.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/08e3e9b152d63bb3495d9a000cd75f74"><gtr:id>08e3e9b152d63bb3495d9a000cd75f74</gtr:id><gtr:otherNames>Li H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D1431F6B-1AE8-4CFC-8621-334FD42583DC"><gtr:id>D1431F6B-1AE8-4CFC-8621-334FD42583DC</gtr:id><gtr:title>Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c3a2f228fb294dc6ddd16042fb4b2fb"><gtr:id>6c3a2f228fb294dc6ddd16042fb4b2fb</gtr:id><gtr:otherNames>Griffin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF9B997E-61BF-4C66-B52A-54A5462DBC50"><gtr:id>CF9B997E-61BF-4C66-B52A-54A5462DBC50</gtr:id><gtr:title>High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/970ea04860398744f5930e967a46b06d"><gtr:id>970ea04860398744f5930e967a46b06d</gtr:id><gtr:otherNames>Wetherill LF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A7A6161C-0AC6-4282-A468-7C7985C283B6"><gtr:id>A7A6161C-0AC6-4282-A468-7C7985C283B6</gtr:id><gtr:title>A conserved proline between domains II and III of hepatitis C virus NS5A influences both RNA replication and virus assembly.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/61f0cf0f16d76c3fe54012bce667060a"><gtr:id>61f0cf0f16d76c3fe54012bce667060a</gtr:id><gtr:otherNames>Hughes M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A5C239FE-09D8-4379-A9A2-C4A8F9177579"><gtr:id>A5C239FE-09D8-4379-A9A2-C4A8F9177579</gtr:id><gtr:title>Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/862ad4091a5cf4b17d716e24135cb6c2"><gtr:id>862ad4091a5cf4b17d716e24135cb6c2</gtr:id><gtr:otherNames>Foster TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/392CA97E-E2A3-48D5-91A2-A9F8379E2158"><gtr:id>392CA97E-E2A3-48D5-91A2-A9F8379E2158</gtr:id><gtr:title>Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/de93f69fde70e65584e320255acc448a"><gtr:id>de93f69fde70e65584e320255acc448a</gtr:id><gtr:otherNames>Wozniak AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4E22D22C-F007-4C0A-8010-82D9CAD329B8"><gtr:id>4E22D22C-F007-4C0A-8010-82D9CAD329B8</gtr:id><gtr:title>The stability of secreted, acid-labile H77/JFH-1 hepatitis C virus (HCV) particles is altered by patient isolate genotype 1a p7 sequences.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b644cc59da2455917bad6669556a176"><gtr:id>1b644cc59da2455917bad6669556a176</gtr:id><gtr:otherNames>Atkins E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/499F2291-DDCD-4572-9F6E-E6BE78C0192F"><gtr:id>499F2291-DDCD-4572-9F6E-E6BE78C0192F</gtr:id><gtr:title>A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c8b5785607e8a5e029d1e32eb03e7c3e"><gtr:id>c8b5785607e8a5e029d1e32eb03e7c3e</gtr:id><gtr:otherNames>Stewart H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/37BC57BD-B342-4B2E-A792-3EAA10B13969"><gtr:id>37BC57BD-B342-4B2E-A792-3EAA10B13969</gtr:id><gtr:title>Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/61f0cf0f16d76c3fe54012bce667060a"><gtr:id>61f0cf0f16d76c3fe54012bce667060a</gtr:id><gtr:otherNames>Hughes M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4EE5A05A-3BC6-4B36-9F39-F6101BDE2FE0"><gtr:id>4EE5A05A-3BC6-4B36-9F39-F6101BDE2FE0</gtr:id><gtr:title>Viroporins: structure, function and potential as antiviral targets.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/37bfcbc2b652be3b994f6fc28b2ffa8d"><gtr:id>37bfcbc2b652be3b994f6fc28b2ffa8d</gtr:id><gtr:otherNames>Scott C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BBCCEC4F-CAA2-42CB-A6A7-9D63271B9FC3"><gtr:id>BBCCEC4F-CAA2-42CB-A6A7-9D63271B9FC3</gtr:id><gtr:title>Expression of hepatitis C virus (HCV) structural proteins in trans facilitates encapsidation and transmission of HCV subgenomic RNA.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f4f3d709f19ac5e7f8f009b80dd878a5"><gtr:id>f4f3d709f19ac5e7f8f009b80dd878a5</gtr:id><gtr:otherNames>Adair R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8390ED92-4EAA-458B-B721-8D1D53A9B16B"><gtr:id>8390ED92-4EAA-458B-B721-8D1D53A9B16B</gtr:id><gtr:title>Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/862ad4091a5cf4b17d716e24135cb6c2"><gtr:id>862ad4091a5cf4b17d716e24135cb6c2</gtr:id><gtr:otherNames>Foster TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/983D8A33-B2AE-4DE3-B217-0A42764AC22F"><gtr:id>983D8A33-B2AE-4DE3-B217-0A42764AC22F</gtr:id><gtr:title>Chimeric GB virus B genomes containing hepatitis C virus p7 are infectious in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c3a2f228fb294dc6ddd16042fb4b2fb"><gtr:id>6c3a2f228fb294dc6ddd16042fb4b2fb</gtr:id><gtr:otherNames>Griffin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB6903DB-E5B9-4ADA-BAD3-C1D3003B6E52"><gtr:id>DB6903DB-E5B9-4ADA-BAD3-C1D3003B6E52</gtr:id><gtr:title>Plugging the holes in hepatitis C virus antiviral therapy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7ba5f4001e6b483d0d809f61ec200770"><gtr:id>7ba5f4001e6b483d0d809f61ec200770</gtr:id><gtr:otherNames>Griffin SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0DC0FBD6-BA40-4E1E-846F-9DBC7671E75B"><gtr:id>0DC0FBD6-BA40-4E1E-846F-9DBC7671E75B</gtr:id><gtr:title>Small molecule ligand docking to genotype specific bundle structures of hepatitis C virus (HCV) p7 protein.</gtr:title><gtr:parentPublicationTitle>Computational biology and chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0dcebb0dbc908b22f0cebf272814d311"><gtr:id>0dcebb0dbc908b22f0cebf272814d311</gtr:id><gtr:otherNames>Laasch N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1476-9271</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/11050C06-95F7-49D7-BFB6-2B1298B423B2"><gtr:id>11050C06-95F7-49D7-BFB6-2B1298B423B2</gtr:id><gtr:title>The hepatitis C virus non-structural protein NS5A alters the trafficking profile of the epidermal growth factor receptor.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24d87c50db64b39131deacbf06e2fe80"><gtr:id>24d87c50db64b39131deacbf06e2fe80</gtr:id><gtr:otherNames>Mankouri J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4B150D22-8478-41BF-85F0-EE0CE551C80F"><gtr:id>4B150D22-8478-41BF-85F0-EE0CE551C80F</gtr:id><gtr:title>Inhibition of hepatitis C virus p7 membrane channels in a liposome-based assay system.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/51185bd414b6559c1592b298209e0aa7"><gtr:id>51185bd414b6559c1592b298209e0aa7</gtr:id><gtr:otherNames>StGelais C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/802CDB35-690E-4EDA-9BD6-7DFA7D24E855"><gtr:id>802CDB35-690E-4EDA-9BD6-7DFA7D24E855</gtr:id><gtr:title>Suppression of a pro-apoptotic K+ channel as a mechanism for hepatitis C virus persistence.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24d87c50db64b39131deacbf06e2fe80"><gtr:id>24d87c50db64b39131deacbf06e2fe80</gtr:id><gtr:otherNames>Mankouri J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/018C9369-0D44-48A2-A3E8-2CBEB14358B2"><gtr:id>018C9369-0D44-48A2-A3E8-2CBEB14358B2</gtr:id><gtr:title>Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/675091a3ea14cf4264f3169e4b4ab5aa"><gtr:id>675091a3ea14cf4264f3169e4b4ab5aa</gtr:id><gtr:otherNames>Walter S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/770A139D-E74B-4EF5-B149-E028B5DF4DE6"><gtr:id>770A139D-E74B-4EF5-B149-E028B5DF4DE6</gtr:id><gtr:title>Release of Infectious Hepatitis C Virus from Huh7 Cells Occurs via a trans-Golgi Network-to-Endosome Pathway Independent of Very-Low-Density Lipoprotein Secretion.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24d87c50db64b39131deacbf06e2fe80"><gtr:id>24d87c50db64b39131deacbf06e2fe80</gtr:id><gtr:otherNames>Mankouri J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9ED03699-7CE9-4449-A277-067892322181"><gtr:id>9ED03699-7CE9-4449-A277-067892322181</gtr:id><gtr:title>&amp;quot;Too little, too late?&amp;quot; Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic?</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c3a2f228fb294dc6ddd16042fb4b2fb"><gtr:id>6c3a2f228fb294dc6ddd16042fb4b2fb</gtr:id><gtr:otherNames>Griffin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/16418CD0-7130-4DAF-A953-385B9F8CF139"><gtr:id>16418CD0-7130-4DAF-A953-385B9F8CF139</gtr:id><gtr:title>NS2 is dispensable for efficient assembly of hepatitis C virus-like particles in a bipartite trans-encapsidation system.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/108d7f9bb5eedbb4e82ebe3c4c0525b7"><gtr:id>108d7f9bb5eedbb4e82ebe3c4c0525b7</gtr:id><gtr:otherNames>Bentham MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7BE041C1-2EE7-4CAE-86C6-31CA278DDA48"><gtr:id>7BE041C1-2EE7-4CAE-86C6-31CA278DDA48</gtr:id><gtr:title>Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/51185bd414b6559c1592b298209e0aa7"><gtr:id>51185bd414b6559c1592b298209e0aa7</gtr:id><gtr:otherNames>StGelais C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF54647C-D6D9-46D8-AB24-56CC0E94B984"><gtr:id>BF54647C-D6D9-46D8-AB24-56CC0E94B984</gtr:id><gtr:title>Inhibition of HCV p7 as a therapeutic target.</gtr:title><gtr:parentPublicationTitle>Current opinion in investigational drugs (London, England : 2000)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c3a2f228fb294dc6ddd16042fb4b2fb"><gtr:id>6c3a2f228fb294dc6ddd16042fb4b2fb</gtr:id><gtr:otherNames>Griffin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1472-4472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/623EA008-647E-4956-A688-9FCDD1F5379E"><gtr:id>623EA008-647E-4956-A688-9FCDD1F5379E</gtr:id><gtr:title>Vps4 and the ESCRT-III complex are required for the release of infectious hepatitis C virus particles.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/069f71bcd262740affe2024bce8eb446"><gtr:id>069f71bcd262740affe2024bce8eb446</gtr:id><gtr:otherNames>Corless L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700124</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>